Exenatide Activates the APPL1-AMPK-PPARα Axis to Prevent Diabetic Cardiomyocyte Apoptosis

Table 2

The results of cardiac function testing.

	LVSP (mmHg)	+ (mmHg/s)	− (mmHg/s)	LVEDP (mmHg)
Control	126.25 ± 4.59	604.55 ± 6.59	623.48 ± 8.85	10.38 ± 0.93
D	105.87 ± 4.08	513.86 ± 10.54	430.48 ± 27.37	17.62 ± 1.74
DI	107.19 ± 4.09	519.31 ± 12.61	417.64 ± 18.67	17.48 ± 1.49
DE	119.11 ± 5.11	580.43 ± 14.72	548.76 ± 24.40	13.64 ± 1.25

Compared with the D group, .
Compared with the DI group, .